A recent study found that the legalization of medical cannabis in the United States was associated with a slight decrease in nonmedical prescription opioid use.
Citing the inconclusive current research on legalization of medical cannabis and its effect on nonmedical prescription opioid (NMPO) use, a recent study examined data from the 2004–2014 National Surveys on Drug Use and Health from adults ages 21 and older with NMPO use (1). The study titled, “Association Between Legal Access to Medical Cannabis and Frequency of Non-Medical Prescription Opioid Use Among U.S. Adults,” was published in the International Journal of Mental Health and Addiction on October 30th, 2023 (1). Researchers concluded that medical cannabis laws (MCL) were associated with a slight decrease in NMPO use (2).
After analyzing the data, researchers found that as a state legalized medical cannabis, there was a 0.5 to 1.5 percentage point decrease in regular to frequent NMPO use and a 2.1 percent point increase in occasional NMPO use (2). They also found that the most significant changes came only from those who had cannabis use disorder (CUD) (1). In those cases, frequent opioid use dropped 4.9 percentage points (3).
“The association of MCL with lower frequency of NMPO use was driven by individuals with cannabis use disorder, highlighting the importance of identifying tradeoffs of cannabis legalization as an intervention to reduce opioid-related harms,” the authors stated in the abstract (1).
In the face of the rising opioid-related deaths in the US, cannabis has been explored as a possible aid to reducing opioid addiction (2).
“There might be some benefits to allowing legal access to medical cannabis in the context of opioid-related harms,” stated Hillary Samples, lead author of the study (2). “However, from a policy perspective, there are much more effective interventions to address the ongoing overdose crisis, such as increasing access to treatment for opioid addiction.”
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.